Lonza, a global leader in biological and cell therapy manufacturing and TiGenix, an advanced biopharmaceutical company focused on developing and commercialising novel therapeutics from allogeneic expanded adipose-derived stem cells in inflammatory and autoimmune diseases, announced today an agreement for the supply of TiGenix's eASC product, Cx601. Under the agreement, Lonza will manufacture material for the Phase 3 trial of Cx601 in the US at Lonza's cell therapy production facility in Walkersville, Maryland .
http://ift.tt/1MfYeTt
http://ift.tt/1MfYeTt
No comments:
Post a Comment